Antje Schubert

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel et al. · The Lancet Oncology · 2018 · 354 citations

Medicine, Hematology, Pharmacology +17

Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: Evidence for a dose–window effect

Teresa Olbrich, Elke Ziegler, Gregor Türk et al. · Gynecologic Oncology · 2010 · 50 citations · Full text

Medicine, Oncology, Pharmacology +12

Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo

Antje Schubert, Thomas Hawighorst, Günter Emons et al. · Breast Cancer Research and Treatment · 2011 · 36 citations · Full text

Medicine, Cancer Biology, Oncology +14

Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH

Carsten Gründker, Gerd Bauerschmitz, Antje Schubert et al. · International Journal of Oncology · 2016 · 22 citations · Full text

Medicine, Molecular Biology, Oncology +17

Expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression

Antje Schubert, Hiltrud Schulz, Günter Emons et al. · Gynecological Endocrinology · 2008 · 12 citations

Medicine, Endocrinology, Oncology +17